BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Foreign entity interest: Novartis International AG in Switzerland is the ultimate parent company with an interest in the listed issues impacting the pharmaceutical industry.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EMILY FELDER | — |
| STEPHEN HOLLAND | — |
| ZACHARY PFISTER | — |
| JOHN REISING New | Scheduler, Operations Director, Member Services Director, Deputy Chief of Staff- Majority Leader Steve Scalise; Operations Director, Rep. Bill Flores; Scheduler, Rep. Austin Scott; Intern, Senator Trent Lott. |
| ADAM STEINMETZ | — |
| DEEMA TARAZI | — |
| ANDREW USYK | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| NOVARTIS INTERNATIONAL AG | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.